THE ACTO TIMES: 2025 SUMMER EDITION

Dear ACTO Members and Readers of The ACTO Times,

I am excited to present the 2025 Summer Edition of The ACTO Times, which highlights the upcoming 2025 Singapore ACTO Annual Meeting and recent advances in Asian cell and gene therapy (CGT). As of 2025, over 100 CGT products have been approved globally, yet no exosome product has received global approval. The US FDA and EMA continue to lead in CGT product approvals, while Asia is experiencing rapid growth, particularly in the CGT market, clinical trials, and exosome development.

Under the leadership of Chairperson Dr. Shimosaka and with the dedicated efforts of the ACTO committee, ACTO has played a pivotal role in advancing precision CGT within Asian regions. In 2024, ACTO launched its official magazine, The ACTO Times, to share the latest developments in global CGT, including translational medicine, regulation, clinical trials, and industry insights. To date, The ACTO Times has published six editions spotlighting global CGT advances and developments in Asian territories.

In this Summer Edition, we spotlight the Singapore ACTO Annual Meeting and highlight recent advances in EV translational medicine. Importantly, we have new established an “Academic Zone” to foster the development of academic translational medicine in future CGT.

We warmly invite you to join the 2025 ACTO Annual Meeting in Singapore this year. This event will bring together experts and leaders in the field to discuss the latest advancements and future directions in cell and gene therapy.

We hope you enjoy this edition and look forward to your continued support and feedback.

Sincerely,

Yen Hua Huang, PhD  

Distinguished Professor, Taipei Medical University  

Editor-in-Chief, The ACTO Times  

ACTO, Asian Cellular Therapy Organization